All In Biotech

NDA 020980 · Karo Hlthcare

Lamisil

Terbinafine Hydrochloride · Topical

Last checked: Nov 20, 2026Latest source record: Jul 17, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Mar 9, 1999

Approved uses

1

Original approval plus efficacy supplements

Registered trials

57

14 Phase 3, 3 recruiting

FAERS reports

1,279

835 serious, 50 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 18, 2025.

Uses - cure most jock itch (tinea cruris) and ringworm (tinea corporis) - relieves itching, burning, cracking andf scaling which accompany this condition

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 9, 1999 Original approval · Type 8 - Partial Rx to OTC Switch ReviewLetter
1 products under this application
  • LAMISIL · TERBINAFINE HYDROCHLORIDE 1% · CREAM, TOPICAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Terbinafine" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective96
  • pruritus77
  • rash75
  • nausea68
  • fatigue63
  • pain62
  • dyspnoea56
  • ageusia50
  • diarrhoea47
  • headache47
  • weight decreased46
  • cough42

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200728
200826
200917
201026
201123
201238
201315
201416
201554
201625
201743
201856
201973
202063
202179
2022148
2023147
2024162
2025157
202683

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 369 on PubMed

Sponsor: Karo Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.